These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35277278)

  • 1. Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea.
    Kim J; Noh JJ; Lee TK; Kim SI; Lee JY; Lee JW; Kim JW
    Gynecol Oncol; 2022 May; 165(2):369-375. PubMed ID: 35277278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of lenvatinib plus pembrolizumab in patients with advanced and recurrent endometrial cancer: a systematic review and meta-analysis.
    Yan G; Du Y; Zhang H; Yan J; Liu Y; Ban Z; Guo YZ; Zeng X
    Front Immunol; 2024; 15():1404669. PubMed ID: 39185408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.
    How JA; Patel S; Fellman B; Lu KH; Hwu P; Ramondetta LM; Westin SN; Fleming ND; Soliman PT; Jazaeri AA
    Gynecol Oncol; 2021 Jul; 162(1):24-31. PubMed ID: 33958211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.
    Zammarrelli WA; Ma W; Espino K; Gordhandas S; Yeoshoua E; Ehmann S; Zhou Q; Iasonos A; Abu-Rustum NR; Aghajanian C; Green AK; Rubinstein MM; Makker V
    Gynecol Oncol; 2023 Nov; 178():27-35. PubMed ID: 37748268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib plus Pembrolizumab Combination Therapy for Advanced or Recurrent Endometrial Cancer: A Single-Center, Retrospective Analysis.
    Tochigi M; Shigeta S; Shimada M; Miyahara S; Hasegawa-Minato J; Shibuya Y; Ishibashi M; Hashimoto C; Tokunaga H; Yaegashi N
    Tohoku J Exp Med; 2024 Feb; 262(2):85-95. PubMed ID: 38008437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world utilization of lenvatinib and pembrolizumab combination therapy for the treatment of endometrial cancer in the USA.
    Wada K; Zhang J; Lee I; Wang Y; Near A; Prabhu VS
    Future Oncol; 2024 Feb; 20(5):257-267. PubMed ID: 37828843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.
    Yonemori K; Fujiwara K; Hasegawa K; Yunokawa M; Ushijima K; Suzuki S; Shikama A; Minobe S; Usami T; Kim JW; Kim BG; Wang PH; Chang TC; Yamamoto K; Han S; McKenzie J; Orlowski RJ; Miura T; Makker V; Man Kim Y
    J Gynecol Oncol; 2024 Mar; 35(2):e40. PubMed ID: 38302725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
    Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
    Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
    Makker V; Colombo N; Casado Herráez A; Santin AD; Colomba E; Miller DS; Fujiwara K; Pignata S; Baron-Hay S; Ray-Coquard I; Shapira-Frommer R; Ushijima K; Sakata J; Yonemori K; Kim YM; Guerra EM; Sanli UA; McCormack MM; Smith AD; Keefe S; Bird S; Dutta L; Orlowski RJ; Lorusso D;
    N Engl J Med; 2022 Feb; 386(5):437-448. PubMed ID: 35045221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
    Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
    Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy.
    Dioun S; Chen L; De Meritens AB; St Clair CM; Hou JY; Khoury-Collado F; Pua T; Hershman DL; Wright JD
    Gynecol Oncol; 2024 Mar; 182():70-74. PubMed ID: 38262241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system.
    Chiba Y; Kagabu M; Osakabe M; Ito R; Sato S; Takatori E; Kaido Y; Nagasawa T; Shoji T; Yanagawa N; Baba T
    Jpn J Clin Oncol; 2024 Apr; 54(4):424-433. PubMed ID: 38251744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System.
    Matsumoto J; Iwata N; Watari S; Ushio S; Shiromizu S; Takeda T; Hamano H; Kajizono M; Araki M; Nasu Y; Ariyoshi N; Zamami Y
    Eur Urol Focus; 2023 Jan; 9(1):141-144. PubMed ID: 35915038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose lenvatinib and anti-programmed cell death protein-1 combination therapy in patients with heavily pre-treated recurrent ovarian and endometrial cancer: a pilot study.
    Shang X; Su H; Chen X; Wang Y; Wan X; Zhang Y; Jin Y; Feng F
    Int J Gynecol Cancer; 2024 Aug; 34(8):1203-1210. PubMed ID: 38658019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line lenvatinib in patients with recurrent endometrial cancer.
    Vergote I; Powell MA; Teneriello MG; Miller DS; Garcia AA; Mikheeva ON; Bidzinski M; Cebotaru CL; Dutcus CE; Ren M; Kadowaki T; Funahashi Y; Penson RT
    Gynecol Oncol; 2020 Mar; 156(3):575-582. PubMed ID: 31955859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab.
    Makker V; Taylor MH; Oaknin A; Casado Herraez A; Orlowski R; Dutta L; Ren M; Zale M; O'Malley DM
    Oncologist; 2021 Sep; 26(9):e1599-e1608. PubMed ID: 34190370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
    Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
    Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
    Taylor MH; Lee CH; Makker V; Rasco D; Dutcus CE; Wu J; Stepan DE; Shumaker RC; Motzer RJ
    J Clin Oncol; 2020 Apr; 38(11):1154-1163. PubMed ID: 31961766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing the Adverse Events Associated with Pembrolizumab and Lenvatinib Therapy in Endometrial Cancer.
    Zribi A; Al Riyami K; Al Zahibi HS; Burney IA
    Sultan Qaboos Univ Med J; 2024 May; 24(2):293-297. PubMed ID: 38828252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
    Motzer R; Alekseev B; Rha SY; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Kopyltsov E; Méndez-Vidal MJ; Kozlov V; Alyasova A; Hong SH; Kapoor A; Alonso Gordoa T; Merchan JR; Winquist E; Maroto P; Goh JC; Kim M; Gurney H; Patel V; Peer A; Procopio G; Takagi T; Melichar B; Rolland F; De Giorgi U; Wong S; Bedke J; Schmidinger M; Dutcus CE; Smith AD; Dutta L; Mody K; Perini RF; Xing D; Choueiri TK;
    N Engl J Med; 2021 Apr; 384(14):1289-1300. PubMed ID: 33616314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.